Excellence in Hemoglobinopathies Research Award Program
Page 2

It is the hope of the NHLBI that the proposals will pave the way to several interdisciplinary approaches to translational research in the hemoglobinopathies, which entails a higher likelihood of high-impact research eventually becoming applied clinical research studies.

The end goal of the studies that will be proposed under this project is centered on the discovery of small molecules, biologics, and biomarkers that can all be utilized in the process of diagnosing, treating, and managing sickle cell disease or the thalassemias.

The NHLBI is set to administer 7 to 10 grant awards with an overall budget of $72.85, with a total cost of $14 million for the year 2013 alone.

The organizations and institutions that will be deemed eligible to submit an application under the Excellence in Hemoglobinopathies Research Award Program are the following:

a) Higher Education Institutions such as Public/State Controlled Institutions of Higher Education and Private Institutions of Higher Education

b) Nonprofits Other Than Institutions of Higher Education

c) For-Profit Organizations such as Small Businesses and other organizations other than Small Businesses

d) State Governments, County Governments, City or Township Governments and Special District Governments

e) Independent School Districts, Public Housing Authorities/Indian Housing Authorities, Native American Tribal Organizations (other than Federally recognized tribal governments), Faith-based or Community-based Organizations, and Regional Organizations.

Excellence in Hemoglobinopathies Research Award Program
  Back to Page 1

About The Author Michael Saunders is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. He also maintains Websites providing resources on artist grants and children grants.

Additional Resources

category - Health Grants

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

---

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---

Pilot Surveillance System for High Impact/Low Prevalence Congenital and Inherited Conditions Program
The Centers for Disease Control and Prevention has recently established the Pilot Surveillance System for High Impact/Low Prevalence Congenital and Inherited Conditions Program wherein it seeks to create and evaluate a surveillance system for congenital and inherited disease conditions.

---

The Collaborative Islet Transplantation Registry Program
The National Institutes of Health has formed a partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in order to establish the The Collaborative Islet Transplantation Registry Program wherein both agencies seek to invite applications that intend to continue initiatives started through the Collaborative Islet Transplantation Registry (CITR).

---